New gut drug shows promise in early colitis trial
NCT ID NCT03100864
Summary
This small study tested a new drug called BI 655130 in 8 people with active ulcerative colitis. The main goal was to understand how the drug works in the gut and to check if it was safe. Researchers measured changes in gut tissue and inflammation markers over 12 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrooke's Hospital
Cambridge, CB2 0QQ, United Kingdom
-
Asklepios Kliniken Westklinikum Hamburg
Hamburg, 22559, Germany
-
UZ Leuven
Leuven, 3000, Belgium
-
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, 24105, Germany
Conditions
Explore the condition pages connected to this study.